Pharmaceutical Department, Usl Umbria 1, XIV Settembre Street, 06132 Perugia, Italy.
Clinical Pathology, Asur Marche, Viale Guido Da Montefeltro, Urbino, Italy.
Med Hypotheses. 2021 Feb;147:110486. doi: 10.1016/j.mehy.2021.110486. Epub 2021 Jan 7.
On March 11, 2020 the World Health Organization (WHO) declared the state of global pandemic caused by the new SARS-CoV-2 (COVID-19). To date, no antivirals directed against SARS-CoV-2 or effective vaccines to combat the viral infection are available. Severe acute respiratory syndrome caused by SARS-CoV-2 is treated empirically with antivirals, anti-inflammatory, anticoagulants. The approval of an effective vaccine still takes time. In this state, it may be useful to find new therapeutic solutions from drugs already on the market. Recent hypotheses suggest that the use of AT-1 receptor antagonists (ARB) in combination with neprilisin inhibitors (NEPi) could indirectly provide clinical benefits to patients with SARS-CoV-2 and cardiac involvement. In this article we investigate and describe a possible innovative pharmacological approach for the treatment of the most severe stages of COVID-19 infection.
2020 年 3 月 11 日，世界卫生组织（WHO）宣布，由新型 SARS-CoV-2（COVID-19）引起的全球大流行状态。迄今为止，尚无针对 SARS-CoV-2 的抗病毒药物或有效疫苗可用于对抗病毒感染。由 SARS-CoV-2 引起的严重急性呼吸综合征采用抗病毒药、抗炎药、抗凝剂进行经验性治疗。有效的疫苗的批准仍需时间。在这种情况下，从已经上市的药物中寻找新的治疗方法可能会很有用。最近的假设表明，AT-1 受体拮抗剂（ARB）与 Neprilysin 抑制剂（NEPi）联合使用可能会间接为 SARS-CoV-2 合并心脏受累的患者提供临床获益。本文探讨并描述了一种针对 COVID-19 感染最严重阶段的治疗的可能的创新性药理学方法。
